-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: Macrophages (grey) attack tumor cells (green)
Manfred Ogris, Magdalena Billerhart, University of Vienna
On phagocytes (also called macrophages) and other immune cells, you can find the ligand for CD47, namely SIRPa
The new treatment concept presented here ensures that the tumor cells themselves produce CD47 blocking and immune activating proteins
Results: CD47 was successfully blocked not only on tumor cells that produced the fusion protein, but also on neighboring tumor cells
DOI
DOI: 10.
Article title
CD47-targeted cancer immunogene therapy: secreted SIRPα-Fc fusion protein eradicates tumors by macrophage and NK cell activation
